These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 33904154)

  • 1. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Modulators in Depression.
    Henter ID; de Sousa RT; Zarate CA
    Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
    Wilkinson ST; Sanacora G
    Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
    Lener MS; Kadriu B; Zarate CA
    Drugs; 2017 Mar; 77(4):381-401. PubMed ID: 28194724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
    McIntyre RS; Jain R
    CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New targets for rapid antidepressant action.
    Machado-Vieira R; Henter ID; Zarate CA
    Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
    Hashimoto K; Malchow B; Falkai P; Schmitt A
    Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):367-77. PubMed ID: 23455590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.
    Henter ID; de Sousa RT; Gold PW; Brunoni AR; Zarate CA; Machado-Vieira R
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):153-166. PubMed ID: 27781556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
    Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
    Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
    Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
    Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
    Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.